ClinicalTrials.gg
Not yet recruitingNCT07923565Updated Nov 6, 2026

CANLINK: Evaluation of the Intralink Intradiscal Device for Low Back Pain Due to Degenerative Disc Disease

An interventional study of Pain treatment in Degenerative Disc Disease(DDD), sponsored by Spinal Simplicity LLC. Not yet recruiting at 1 site in Canada. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Spinal Simplicity LLC · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
22 Years to 80 Years
Sex
All
01

Study summary

A single site, prospective study to evaluate the safety and performance of the Intralink device in participants with chronic or recurrent non-radicular discogenic low back pain (LBP) due to degenerative disc disease (DDD).

Read the detailed description

This study designed to evaluate the safety and effectiveness of the Intralink device in participants with chronic or recurrent non-radicular discogenic LBP due to DDD.

02

Conditions studied

  • Degenerative Disc Disease(DDD)
03

In context

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Spinal Simplicity LLC is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 22 - 80 years
  • Degenerative Disc Disease (DDD)
  • Six (6) months or more of chronic low back pain and failure to respond to conservative care
  • Pain medication use has been stable for at least 30 days

Exclusion criteria

Exclusion Criteria:

  • (BMI) >40 kg/m2
  • Uncontrolled diabetes
  • Symptomatic DDD at more than 2 levels
  • Previously diagnosed Paget's disease, osteomalacia, other metabolic bone disease
  • Target disc collapse (disc height loss)
  • Active systemic or spine infection
  • Recent (\< 3 months) therapeutic interventions (i.e., IDET, PRP or stem cell injections) on the target disc(s)
  • Any surgery at the index level (i.e. discectomy or intradiscal ablation) or any extensive surgery (fusion, artificial disc, laminectomy) at any lumbar level
  • Previous treatment of target disc level with injection, intradiscal injection, trigger point injection, facet or medial branch block within 90 days of enrollment
  • Active
  • Spinal tumor
  • Presence of extruded disc herniation or wide annular fissures confluent with large disc protrusions at the symptomatic level.
  • Symptomatic spinal stenosis (i.e., neurogenic claudication)
  • Congenital or degenerative spondylolisthesis greater than grade 1
  • Currently participating in another study that could interfere with the outcome measures of this study
  • Known anaphylactic reaction to contrast dye
  • Opioid medication >60 MME/day within 60 days of enrollment
  • If female, participants who are pregnant or are trying to become pregnant during the course of the trial (due to risks of additional radiation exposures); participants of that are sexually active must use a reliable form of and present a negative urine pregnancy test prior to the implant procedure
  • Other protocol defined inclusion/exclusion may apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment

    Intralink Device

    Device: Pain treatment

Interventions

  • DevicePain treatment

    Device: Intralink

    Also known as: Intralink

06

What researchers measure

Primary outcomes

  1. Oswestry Disability Index (ODI)

    Change from baseline in mean disability scores using Oswestry Disability Index (ODI) ODI is a self-reported questionnaire widely used to track changes in a patient's condition over time and evaluate the effectiveness of treatments for low back pain. The ODI consists of 10 sections, each addressing a specific aspect of daily functioning. A higher score indicates greater disability. The final score/index ranges from 0-100 scale. A score of 0-20 reflects minimal disability, 21-40 moderate disability, 41-60 severe disability, 61-80 crippled, and 81-100 bed bound.

    Time frame: 1 Month compared to Baseline

  2. Assess occurrence of serious adverse events post-treatment.

    Frequency of serious adverse events post implant

    Time frame: Through 1 Month post procedure

Secondary outcomes

  1. Evaluate type of adverse events

    Incidence and type of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline through 6 months post procedure

  2. Assess change from baseline in mean disability scores using Oswestry Disability Index (ODI) post-procedure

    Change from baseline in mean disability scores using Oswestry Disability Index (ODI) ODI is a self-reported questionnaire widely used to track changes in a patient's condition over time and evaluate the effectiveness of treatments for low back pain. The ODI consists of 10 sections, each addressing a specific aspect of daily functioning. A higher score indicates greater disability. The final score/index ranges from 0-100 scale. A score of 0-20 reflects minimal disability, 21-40 moderate disability, 41-60 severe disability, 61-80 crippled, and 81-100 bed bound.

    Time frame: 3, 6, 12, and 24 months post procedure

  3. Assess change from baseline in mean pain scores using Visual Analog Scale (VAS)

    Change from baseline in mean pain scores using Visual Analog Scale (VAS) The VAS is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-100 mm scale, with zero meaning "no pain" and 100 meaning "the worst pain imaginable".

    Time frame: 1, 3, 5, 12, and 24 months post procedure

  4. Evaluate change of baseline spinal instability using flexion-extension radiographic imaging

    Proportion of participants with a 50% or greater reduction from baseline value in spinal instability (when baseline value is greater than or equal to 1.0), as measured by vertebral angular motion and sagittal plane translations on flexion-extension radiographs

    Time frame: Baseline, 1, 3, 5, 12, and 24 months

  5. Assess use of escalated interventions post-procedure

    Any of the following count as escalated interventions: increase pain medication use and additional interventions - i.e. injections and surgical interventions at the treatment level.

    Time frame: From Baseline to 1, 3, 6, 12, and 24 months

  6. Patient Global Impression of Change (PGIC)

    The Patient Global Impression of Change (PGIC) PGIC is a standardized tool designed to assess a patient's self-reported perception of improvement or worsening in their health status over time. The PGIC consists of 1 question, using a 1 to 7 scale: 1-Very Much Improved to 7-Very much Worse.

    Time frame: 1, 3, 6, 12, and 24 months post-implant

  7. Patient Satisfaction

    Patient Satisfaction Survey is designed to assess a patient's self-reported satisfaction or dissatisfaction on a 5 point scale. 1- Very Satisfied to 5-Very Dissatisfied

    Time frame: 1, 3, 6, 12, and 24 months post-implant

07

Study locations

1 site
  • Beam Radiology
    Calgary, Canada
08

References and documents

Publications

  • Hedman T, Yu J, Singh H, Deer T. Early Clinical Results of Intervertebral Joint Stabilization by Injectable Load-Sharing Polymers. J Pain Res. 2023 Aug 10;16:2777-2789. doi: 10.2147/JPR.S413104. eCollection 2023. PubMed 37583391 ↗
  • Hedman T, Rogers A. Pathomechanics of Early-Stage Lumbar Intervertebral Disc Degradation Leading to Discogenic Pain-A Narrative Review. Bioengineering (Basel). 2025 Apr 5;12(4):389. doi: 10.3390/bioengineering12040389. PubMed 40281749 ↗
  • Hedman T, Rogers A, Beall D. A Self-Polymerizing Mesh of Nano-Tethers for the Mechanical Constraint of Degraded Intervertebral Discs-A Review of 25 Years of Pre-Clinical and Early Clinical Research. Bioengineering (Basel). 2024 May 24;11(6):535. doi: 10.3390/bioengineering11060535. PubMed 38927771 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923565
Lead sponsor
Spinal Simplicity LLC
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Echo Cundiff, Director of Clinical Research
Contact
ecundiff@spinalsimplicity.com
815-848-4189

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion